Table 2.
Characteristics of the malignancy group.
| Patient ID in EMRS | Age at onset of DM (Y) | Gender | Tumor entity | Time gap between malignancy and DM (M) | MSAs & MAAs |
|---|---|---|---|---|---|
| 14015340 | 46 | Female | Breast | −13 | Ro52 |
| 12532821 | 53 | Male | Lung | 1 | Ro52 |
| 12787817 | 70 | Male | Nasopharyngeal | 11 | TIF1γ |
| 13912388 | 53 | Female | Gastric | 0 | TIF1γ, Mi2β, PM-SCL100 |
| 13416964 | 65 | Male | Colorectal | 1 | Mi2α, Mi2β |
| 01275122 | 69 | Male | Gastric | −120 | TIF1γ, Mi2α, PM-SCL75 |
| 13163699 | 77 | Female | Esophageal | −98 | TIF1γ, Ro52 |
| 03375570 | 61 | Female | Fallopian tube | 0 | Ro52 |
| 13052536 | 67 | Male | Lung | 9 | MDA5 |
| 12967053 | 39 | Female | Nasopharyngeal | 0 | TIF1γ, Ro52 |
| 07571818 | 68 | Female | Thyroid | −87 | Ro52 |
| 12041289 | 46 | Female | Cervical | −35 | Mi2α, Mi2β, PM-SCL75 |
ID, identification; EMRS, electronic medical record system; Y, years of life; M, months; MSA, myositis specific autoantibody; MAA, myositis associated autoantibody. A minus number in the column of “time gap between malignancy and DM” indicates the malignancy was reported prior to the diagnosis of DM.